2,270 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by MQS Management LLC

MQS Management LLC purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,270 shares of the specialty pharmaceutical company’s stock, valued at approximately $253,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Capital World Investors purchased a new position in shares of Jazz Pharmaceuticals in the first quarter worth approximately $171,943,000. Swedbank AB acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $106,936,000. Rubric Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $65,812,000. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares in the last quarter. Finally, Baupost Group LLC MA boosted its position in shares of Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after buying an additional 440,552 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $124.27 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market cap of $7.51 billion, a PE ratio of 17.50, a price-to-earnings-growth ratio of 1.07 and a beta of 0.57. The stock has a 50-day moving average of $111.61 and a 200-day moving average of $110.18. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Royal Bank of Canada upped their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, October 23rd. Wells Fargo & Company decreased their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Finally, Robert W. Baird dropped their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $175.00.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.